Hyderabad: Granules India Ltd has reported a 39% rise in consolidated profit after tax for the second quarter ended Sept 30, 2026, to ₹182 crore from ₹131 crore in the corresponding quarter of the previous fiscal.Revenue from operations rose 20% year-on-year to ₹1,560 crore, compared with ₹1,297 crore in Q2FY26, the company said on Monday.The company said North America remained its largest market, contributing 72% of revenue during the quarter, albeit down from 76% in the year-ago period, while Europe’s share rose to 16% from 12% a year earlier. Finished dosages accounted for 73% of revenue, followed by active pharmaceutical ingredients at 13%, pharmaceutical formulation intermediates at 10%, and peptide CDMO at 3%.Granules said the performance came despite higher input and logistics costs linked to tensions in West Asia. It also cited its continued shift towards complex generics and peptide CDMO, along with new ANDA filings, as part of its ongoing business strategy.Dr Krishna Prasad Chigurupati, chairman and managing director, Granules India Ltd, said though cost pressures will persist, the company is working with customers to manage them with a lag. “We filed two potential first-to-file ANDAs in H1… and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 Cr to invest in R&D, manufacturing and quality.”
About The Author
